Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CRHBP | P24387 | 2/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21286723 | 0.81 | KMT2A (0.38) | SMN1; SMN2KMT2ALDHAGAA | |
| SCHEMBL21915155 | 0.81 | KMT2A (0.38) | SMN1; SMN2KMT2ALDHAGAA | |
| SCHEMBL21625367 | 0.81 | KMT2A (0.38) | SMN1; SMN2KMT2ALDHAGAA | |
| SCHEMBL24250654 | 0.81 | KMT2A (0.38) | SMN1; SMN2KMT2ALDHAGAA | |
| SCHEMBL20997406 | 0.81 | KMT2A (0.38) | SMN1; SMN2KMT2ALDHAGAA | |
| SCHEMBL6124181 | 0.81 | ABCG2 (0.34) | ITGB2ICAM1ITGALSIGMAR1 | |
| SCHEMBL20997082 | 0.78 | KMT2A (0.39) | SMN1; SMN2KMT2AGAA | |
| SCHEMBL21286816 | 0.78 | KMT2A (0.39) | SMN1; SMN2KMT2AGAA | |
| SCHEMBL21625351 | 0.78 | KMT2A (0.39) | SMN1; SMN2KMT2AGAA | |
| SCHEMBL21915010 | 0.78 | KMT2A (0.39) | SMN1; SMN2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487099-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120107328-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2012-05-03 | — | — | US | disclosed |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107328-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | ITGB2 2250/4885ICAM1 3308/4885ITGAL 2081/4885 |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | ITGB2 3949/4885ICAM1 3782/4885ITGAL 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.